Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2020
SIETES contiene 93011 citas

 
 
 1 a 20 de 5020 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Zhu H, Bateman BT, Gray KJ, Hernandez-Diaz S, Mogun H, Starub L, Huybrechts KF. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. BMJ 2020;369:20 de mayo. [Ref.ID 103628]
2. Cita con resumen
Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ 2020;369:29 de abril. [Ref.ID 103626]
3. Cita con resumen
Bunyavanich S, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 2020:1. [Ref.ID 103625]
6. Cita con resumen
Lafaurie M, Olivier P, Khouri C, Atzenhoffer M, Bihan K, Durrieu G, Montastruc J-L. Myocardial infarction and ischemic stroke with vasoconstrictors used as nasal decongestant for common cold: a French pharmacovigilance survey. Eur J Clin Pharmacol 2020;76:603-4. [Ref.ID 103616]
8. Cita con resumen
Sakoulas G, El Sahly H, Ellison III RT. Chloroquine and hydroxychloroquine: old drugs in a new COVID-19 world. Journal Watch 2020:1. [Ref.ID 103608]
10. Cita con resumen
Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Chinitz LA, Jankelson L. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 2020:24 de abril. [Ref.ID 103600]
11.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dal-Ré R, Kesselheim AS, Bourgeois FT. Increasing access to FDA inspection reports on irregularities and misconduct in clinical trials. JAMA 2020:23 de abril. [Ref.ID 103599]
12. Cita con resumen
Di Maio M, Audisio M, Cardone C, De Luca E, Gargiulo P, Zichi C, Perrone F. The use of not-negative conclusions to describe results of formally negative trials presented at oncology meetings. JAMA Oncology 2020:1. [Ref.ID 103598]
13. Cita con resumen
Iacobucci G. Sixty seconds on . . . the RECOVERY trial. BMJ 2020;369:20 de abril. [Ref.ID 103597]
14.Enlace a cita original Cita con resumen
Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020;369:8 de abril. [Ref.ID 103595]
15.Enlace a cita original Cita con resumen
Mullard A. Flooded by the torrent: the COVID-19 drug pipeline. Lancet 2020;395:8 de abril. [Ref.ID 103591]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
PM Group. Gilead’s remdesivir appears to fail in leaked COVID-19 trial data. PMLiVE 2020:24 de abril. [Ref.ID 103590]
17.Enlace a cita original Cita con resumen
Suissa S, Dell'Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD. Cohort study in real-world clinical practice. Chest 2020;157:abril. [Ref.ID 103589]
18. Cita con resumen
19. Cita con resumen
Luo Q, Qin T. Managing clinical trials for covid-19: the importance of ethics committees. BMJ 2020;369:3 de abril. [Ref.ID 103584]
20. Cita con resumen
Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ 2020;368:27 de marzo. [Ref.ID 103583]
Seleccionar todas
 
 1 a 20 de 5020 siguiente >>